Therapy News and Research

RSS

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

LWW sponsors symposium on wound care

The 25th Anniversary Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 30-October 3, 2010, at the Gaylord Palms Hotel and Convention Center in Kissimee, FL. The symposium is sponsored by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA).

17 Jun 2010

St. Jude Medical's EnSite Contact Technology platform receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of the EnSite Contact™ Technology platform at the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques (CardioStim).

17 Jun 2010

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.

17 Jun 2010

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

The largest study to date to examine methods to prevent HIV infection among breastfeeding infants concludes that giving antiretroviral drugs to HIV-infected breastfeeding mothers in sub-Saharan Africa or giving an HIV-fighting syrup to their babies are both effective.

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

The American Society for Radiation Oncology (ASTRO) commends the Medicare Payment Advisory Commission (MedPAC) for highlighting concerns about physician self-referral in cancer care in its report released yesterday. We urge the commission to make recommendations to Congress to end abuses of the physician self-referral law in radiation oncology enabled by the "in-office ancillary services exception."

17 Jun 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

Ipsen, Inspiration receive positive opinion in Europe for orphan drug status of OBI-1 in treatment of hemophilia

Ipsen and Inspiration Biopharmaceuticals, Inc. announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug status for OBI-1 for the treatment of hemophilia.

17 Jun 2010

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

17 Jun 2010

Therapy News and Research

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

LWW sponsors symposium on wound care

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

St. Jude Medical's EnSite Contact Technology platform receives European CE Mark approval

Scientific American publishes article on "rebirth" of DNA vaccines

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

CINJ researchers combine series of vaccination injections to treat prostate cancer

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

Research studies may lead to future development of cell transplant therapy for ALS

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

Daily use of probiotics reduces VAP in critically ill patients: New research

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

Ipsen, Inspiration receive positive opinion in Europe for orphan drug status of OBI-1 in treatment of hemophilia

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News